ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated Project from Cell Line Development to GMP Manufacturing
ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of their lead antibody candidate. ProBioGen's CHO.RiGHT® cell line development including their latest DirectedLuck® transposase and platform processes enable the development to provide a ...
Source: pharmiweb.com